Efficacy and safety of a tofacitinib-based immunosuppressive regimen after kidney transplantation: Results from a long-term extension trial

Stephan Busque*, Flavio G. Vincenti, Helio Tedesco Silva, Philip J. O’Connell, Atsushi Yoshida, John J. Friedewald, Steven M. Steinberg, Klemens Budde, Emine N. Broeders, Yon Su Kim, Carolyn M. Hahn, Huihua Li, Gary Chan

*Corresponding author for this work

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

Background. Tofacitinib is an oral Janus kinase inhibitor. This open-label, long-term extension (LTE) study (NCT00658359) evaluated long-term tofacitinib treatment in stable kidney transplant recipients (n = 178) posttransplant. Methods. Patients who completed 12 months of cyclosporine (CsA) or tofacitinib treatment in the phase IIb parent study (NCT00483756) were enrolled into this LTE study, evaluating long-term tofacitinib treatment over months 12 to 72 posttransplant. Patients were analyzed by tofacitinib less-intensive (LI) or more-intensive (MI) regimens received in the parent study. For both groups, tofacitinib dose was reduced from 10 to 5 mg twice daily by 6 months into the LTE. Patients were followed up through month 72 posttransplant, with a focus on month 36 results. Results. Tofacitinib demonstrated similar 36-month patient and graft survival rates to CsA. Biopsy-proven acute rejection rates at month 36 were 11.2% for CsA, versus 10.0% and 7.4% (both P > 0.05) for tofacitinib LI and MI, respectively. Least squares mean estimated glomerular filtration rates were 9 to 15 mL/min per 1.73 m 2 higher for tofacitinib versus CsA at month 36. The proportions of patients with grade 2/3 interstitial fibrosis and tubular atrophy in month 36 protocol biopsies were 20.0% for LI and 18.2% for MI (both P > 0.05) versus 33.3% for CsA. Kaplan-Meier cumulative serious infection rates at month 36 were numerically higher for tofacitinib LI (43.9%; P = 0.45) and significantly higher for MI (55.9%; P < 0.05) versus CsA (37.1%). Conclusions. Long-term tofacitinib continued to be effective in preventing renal allograft acute rejection and preserving renal function. However, long-term tofacitinib and mycophenolic acid product combination was associated with persistent serious infection risk.

Original languageEnglish (US)
Article numbere380
JournalTransplantation Direct
Volume4
Issue number9
DOIs
StatePublished - Sep 2018

ASJC Scopus subject areas

  • Transplantation

Fingerprint Dive into the research topics of 'Efficacy and safety of a tofacitinib-based immunosuppressive regimen after kidney transplantation: Results from a long-term extension trial'. Together they form a unique fingerprint.

  • Cite this

    Busque, S., Vincenti, F. G., Tedesco Silva, H., O’Connell, P. J., Yoshida, A., Friedewald, J. J., Steinberg, S. M., Budde, K., Broeders, E. N., Kim, Y. S., Hahn, C. M., Li, H., & Chan, G. (2018). Efficacy and safety of a tofacitinib-based immunosuppressive regimen after kidney transplantation: Results from a long-term extension trial. Transplantation Direct, 4(9), [e380]. https://doi.org/10.1097/TXD.0000000000000819